Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01063439
Other study ID # BuEAM-DLBCL
Secondary ID
Status Recruiting
Phase Phase 2
First received February 4, 2010
Last updated December 1, 2010
Start date January 2010
Est. completion date February 2015

Study information

Verified date August 2010
Source Inje University
Contact Won Sik Lee, Dr. PhD.
Phone 82-51-890-6407
Email wonsik112@gmail.com
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) including intravenous busulfan instead of BCNU of standard BEAM as a conditioning for autologous stem cell transplantation in patients with NHL.


Description:

Among the high-dose conditioning regimens commonly used in patients with NHL are BEAM (BCNU, etoposide, cytarabine, and melphalan), BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide), CBV (cyclophosphamide, carmustine, etoposide), and combination regimen with total body irradiation. Three-year progression free survival of patients with NHL received above high-dose chemotherapy followed by autologous stem cell rescue was reported as 40-50%, which is still unsatisfactory.

Busulfan (Bu)-based preparative regimens, which are commonly used with allogeneic SCT have also been studied with ASCT for lymphomas.

The development of intravenous busulfan achieved 100% bioavailability bypassing the oral route and increased safety and reliability of generating therapeutic busulfan levels, maximizing efficacy.

Recently, one prospective study showed that a combination conditioning regimen of i.v. busulfan, cyclophosphamide, etoposide was found to be well tolerated and seemed to be effective in patients with aggressive NHL.

Another prospective study for multiple myeloma patients showed that i.v. busulfan and melphalan conditioning regimen made no grade 3-4 non-hematological complication.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date February 2015
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender Both
Age group N/A to 65 Years
Eligibility Inclusion Criteria:

- Patients with a high-intermediate/high risk international prognostic index at a diagnosis or with salvage chemotherapy-sensitive relapse/refractory non Hodgkin's lymphoma

- Patients with histologically confirmed diffuse large B cell lymphoma at diagnosis

- Patients treated with rituximab based regimen previously

- Patients who have not received therapy with high-dose chemotherapy and stem cell transplantation

- Life expectation of at least 3 months

- ECOG performance status = 2 (See Appendix II)

- Adequate hepatic function (serum bilirubin less than 2.0 mg/dL, AST and ALT less than three times the upper normal limit)

- Adequate renal function (serum creatinine less than 2.0 mg/dL).

- Adequate cardiac function (ejection fraction = 45% on MUGA scan or echocardiogram).

- Adequate bone marrow function (ANC = 1,000/mm3 and platelet count = 75,000/mm3).

- All patients are fully informed about the nature and purpose of this study and informed consent should be given before the start of treatment. All patients should fully understand the right of trial abandon without any disadvantage

Exclusion Criteria:

- Patients with central nervous system involvement of lymphoma

- Patients positive for human immunodeficiency virus

- Pregnant or breast feeding woman

- Young woman without pregnancy test prior to treatment or pregnancy test reveals positive.

- Young woman without a reliable and proper contraceptive method

- Man being not willing to contraception

- Concurrent history of neoplasm other than NHL with life expectancy less than 3 months (except for curatively treated non-melanoma skin cancer or in-situ uterine cervix cancer).

- History of clinically significant cardiac dysfunction (e.g. congestive heart failure, symptomatic coronary artery disease, medically uncontrolled arrhythmia) or myocardial infarction within 12 months

- A psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.

- Significant infection or uncontrolled bleeding

- Enrollment of other clinical trials within 4 weeks prior to treatment

- Any preexisting medical condition of sufficient severity to prevent full compliance with the study

- Patient being not willing to or unable to obey study protocol

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Busulfan, Etoposide, Cytarabine, Melphalan
Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day

Locations

Country Name City State
Korea, Republic of Inje University Busan Paik Hospital Busan
Korea, Republic of Asan Medical Center, University of Ulsan Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Yeonsei University Hospital Seoul
Korea, Republic of Ulsan University Hospital Ulsan

Sponsors (1)

Lead Sponsor Collaborator
Inje University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary progression-free survival three year No
Secondary overall survival three year No
Secondary Response rate according to the International Working Group criteria after 2 month No
Secondary Adverse events From start of conditioning to discharge Yes
Secondary •Pharmacogenetic study Pharmacogenetic study for predictive or prognostic markers using blood samples After 3 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06014073 - TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Recruiting NCT02007811 - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination Phase 1/Phase 2
Terminated NCT00909948 - Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant Phase 1
Completed NCT00665314 - Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). Phase 2
Recruiting NCT05370547 - Chidamide Bridging for CAR-T Therapy Phase 1/Phase 2
Recruiting NCT06285422 - Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) Phase 1
Withdrawn NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Phase 1/Phase 2
Completed NCT00477945 - Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL Phase 1
Terminated NCT00038818 - CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation N/A
Withdrawn NCT01789723 - Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1
Completed NCT01610180 - Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Phase 2
Terminated NCT00714259 - Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Phase 2/Phase 3
Completed NCT01018758 - Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy Phase 2
Completed NCT00001830 - Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants Phase 1
Completed NCT01527422 - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL Phase 1/Phase 2
Completed NCT00834951 - Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma Phase 2
Recruiting NCT04497688 - Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma N/A
Completed NCT00597714 - Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Phase 2
Completed NCT00001430 - A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas Phase 2